ABUS (Arbutus Biopharma Corporation) צמיחת רווחי EPS רבעונית
Arbutus Biopharma cash flows are based on LNP technology royalties and the development of hepatitis B therapies. The quarterly EPS trend on the GURU.Markets service chart confirms growth rates, where 833.90 reflects the metric's most recent value. Leadership in drug delivery strengthens the company's position, while delegating tests to CRO laboratories under internal patent control minimizes strategic risks.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_ABUS_-_Arbutus-Biopharma_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "arbutusbio.com (ABUS): צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים מ-04.07.2022 עד 15.11.2026 | 👁️GURU.Markets👁️")
Arbutus Biopharma (ABUS) - פילוחי מדדים ודוחות פיננסיים
The investment attractiveness of Arbutus Biopharma (ABUS) is determined by the volatility of fundamental multiples amid high uncertainty. The dynamics of quarterly earnings per share measure the rate of change in net income, revealing hidden business imbalances prior to official reports. This metric assesses capitalization efficiency, which is critical given the limited resources of a biotech firm. For Arbutus Biopharma (ABUS), this indicator highlights the risks associated with dependence on the outcomes of patent disputes with Moderna. EPS growth here serves as a signal of resilience against potential clinical development failures.
